Market Closed -
Nasdaq
21:00:00 07/06/2024 BST
5-day change
1st Jan Change
13.28
USD
-0.60%
-5.48%
-36.73%
SI-BONE, Inc. Updates Financial Guidance for 2023
SI-BONE updating its 2023 worldwide revenue guidance to be in the range of $128 million to $131 million, implying growth of approximately 20% to 23%.
Transcript : SI-BONE, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 11:20 AM
05-14
Morgan Stanley Trims Price Target on SI-Bone to $25 From $26, Keeps Overweight Rating
05-07
MT
Transcript : SI-BONE, Inc., Q1 2024 Earnings Call, May 06, 2024
05-06
Earnings Flash (SIBN) SI-BONE Posts Q1 Revenue $37.9M, vs. Street Est of $36.5M
05-06
MT
SI-BONE, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-06
CI
Si-Bone, Inc. Increases Revenue Guidance for 2024
05-06
CI
Piper Sandler Initiates SI-Bone With Overweight Rating, Price Target is $25
03-28
MT
Transcript : SI-BONE, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 08:30 AM
03-12
Morgan Stanley Raises SI-Bone Price Target to $26 From $25, Maintains Overweight Rating
02-27
MT
Truist Securities Adjusts SI-Bone Price Target to $24 From $26, Maintains Buy Rating
02-27
MT
Transcript : SI-BONE, Inc., Q4 2023 Earnings Call, Feb 26, 2024
02-26
Earnings Flash (SIBN) SI-BONE Posts Q4 Revenue $38.9M, vs. Street Est of $38.6M
02-26
MT
SI-BONE, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
02-26
CI
SI-BONE, Inc. Provides Earnings Guidance for the Year 2024
02-26
CI
Si-bone Insider Sold Shares Worth $808,591, According to a Recent SEC Filing
02-21
MT
SI-Bone Implant Receives Expanded FDA Approval
01-30
MT
SI-Bone Shares Up After Receiving FDA Approval for Expanded Device Use
01-30
DJ
SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application
01-30
CI
SI-Bone, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023
01-08
CI
Truist Securities Adjusts Price Target on SI-Bone to $26 From $25, Maintains Buy Rating
12-22
MT
Truist Securities Raises SI-Bone Price Target to $25 From $22, Maintains Buy Rating
12-12
MT
Cantor Fitzgerald Adjusts SI-Bone's Price Target to $25 From $30, Maintains Overweight Rating
11-07
MT
Morgan Stanley Adjusts Price Target on SI-Bone to $25 From $30, Maintains Overweight Rating
11-07
MT
Needham Adjusts Price Target on SI-Bone to $25 From $32, Maintains Buy Rating
11-07
MT
Transcript : SI-BONE, Inc., Q3 2023 Earnings Call, Nov 06, 2023
11-06
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
More about the company
Last Close Price
13.28
USD
Average target price
25.56
USD
Spread / Average Target
+92.44%
Consensus
1st Jan change
Capi.
-36.73% 547M -24.88% 7.32B +7.04% 6.66B +15.10% 5.5B -15.87% 4.88B +14.96% 4.1B -21.75% 3.89B -25.03% 2.83B +44.01% 2.31B +1.98% 2.07B
Medical Equipment
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1